Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027 (for specialized target groups only)

The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over time
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news